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Abstract
Background: The objective of this study was to compare the cost-effectiveness of the fixed-dose 
combination (FDC) of tiotropium + olodaterol Respimat® FDC with tiotropium alone for patients 
with chronic obstructive pulmonary disease (COPD) in the Italian health care setting using a newly 
developed patient-level Markov model that reflects the current understanding of the disease.
Methods: While previously published models have largely been based around a cohort approach 
using a Markov structure and GOLD stage stratification, an individual-level Markov approach 
was selected for the new model. Using patient-level data from the twin TOnado trials assessing 
Tiotropium + olodaterol Respimat® FDC versus tiotropium, outcomes were modelled based on 
the trough forced expiratory volume (tFEV1) of over 1000 patients in each treatment arm, tracked 
individually at trial visits through the 52-week trial period, and after the trial period it was assumed 
to decline at a constant rate based on disease stage. Exacerbation risk was estimated based on 
a random-effects logistic regression analysis of exacerbations in UPLIFT. Mortality by age and 
disease stage was estimated from an analysis of TIOSPIR trial data. Cost of bronchodilators 
and other medications, routine management, and costs of treatment for moderate and severe 
exacerbations for the Italian setting were included. A cost-effectiveness analysis was conducted 
over a 15-year time horizon from the perspective of the Italian National Health Service.
Results: Aggregating total costs and quality-adjusted life years (QALYs) for each treatment 
cohort over 15 years and comparing tiotropium + olodaterol Respimat® FDC with tiotropium 
alone, resulted in mean incremental costs per patient of €1167 and an incremental cost-
effectiveness ratio (ICER) of €7518 per additional QALY with tiotropium + olodaterol 
Respimat® FDC. The lung function outcomes observed for tiotropium + olodaterol Respimat® 
FDC in TOnado drove the results in terms of slightly higher mean life-years (12.24 versus 
12.07) exacerbation-free months (11.36 versus 11.32) per patient and slightly fewer moderate 
and severe exacerbations per patient-year (0.411 versus 0.415; 0.21 versus 0.24) versus 
tiotropium. Probabilistic sensitivity analyses showed tiotropium + olodaterol Respimat® FDC 
to be the more cost-effective treatment in 95.2% and 98.4% of 500 simulations at thresholds of 
€20,000 and €30,000 per QALY respectively.
Conclusion:: Tiotropium + olodaterol Respimat® FDC is a cost-effective bronchodilator in the 
maintenance treatment of COPD for the Italian health care system.
Keywords: bronchodilators, COPD, cost-effectiveness, economic evaluation, fixed-dose 
combination
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Introduction
Chronic obstructive pulmonary disease (COPD) 
is characterized by persistent airflow limitation 
that is not fully reversible, resulting in declining 
respiratory function and quality of life (QoL) and 
an increased risk of mortality. According to 
World Health Organization (WHO) estimates, 
210 million people worldwide had COPD in 
2011 and it is projected to become the fifth lead-
ing cause of disability-adjusted life years (DALYs) 
lost and the third leading cause of death world-
wide in 2030 [World Health Organization, 
2011]. The decline in lung function of COPD 
patients tends to be accompanied by intermittent 
acute exacerbations. Exacerbations often result 
in hospitalization, increasing the economic bur-
den of COPD and have a considerable negative 
impact on QoL and daily activities [Burge and 
Wedzicha, 2003].
Effective pharmacological interventions for COPD 
are available, and international guidelines recom-
mend that all patients who are symptomatic merit 
a trial of drug treatment. The mainstay of COPD 
maintenance treatment are long-acting broncho-
dilators, such as long-acting muscarinic antago-
nists (LAMAs) and long-acting beta adrenergics 
(LABAs). Combinations of LAMAs and LABAs 
increase forced expiratory volume in one second 
(FEV1) among other spirometric variables, reduce 
dyspnea and improve QoL versus one bronchodi-
lator given alone [Tashkin and Ferguson, 2013]. 
Tiotropium + olodaterol Respimat®, a fixed-dose 
combination (FDC) of tiotropium (LAMA) and 
olodaterol (LABA), has recently been approved 
and marketed in the US [US Food and Drug 
Administration, 2015] and Europe [European 
Medicines Agency, 2016] to relieve symptoms in 
adult patients with COPD. The 1-year effective-
ness of tiotropium + olodaterol Respimat® FDC 
versus its mono components was assessed in 
the TOnado trials, two twin 52-week clinical tri-
als, where tiotropium + olodaterol Respimat® 
FDC demonstrated superiority in lung function, 
QoL assessed by Saint George’s Respiratory 
Questionnaire, and breathlessness assessed by 
the Transition Dyspnea Index.
A cost-effectiveness model was developed to 
assess the long-term benefits and costs of tiotro-
pium + olodaterol Respimat® FDC as compared 
with tiotropium, given tiotropium’s place as the 
most prescribed long-acting bronchodilator for 
COPD. Understanding of disease progression has 
evolved over time, thus raising the need for new 
model structures to more accurately predict out-
comes in COPD patients compared with previous 
published models. For instance, when analysing 
long-term patient data [Tantucci and Modina, 
2012; Tashkin and Ferguson, 2013] it has been 
shown that lung function decline is faster in 
the less severe patients while it slows as severity 
worsens. When it comes to the modelling of exac-
erbations, ECLIPSE data also showed that the 
most important predictor of an exacerbation are 
previous ones, followed by lung function [Hurst 
et al. 2010] rather than lung function alone.
This article describes a newly developed cost-
effectiveness model using an individual patient-
level approach to assess tiotropium + olodaterol 
Respimat® FDC compared with tiotropium in the 
Italian health care setting. The model reflects the 
current understanding of COPD and was devel-
oped to inform healthcare decision-makers on the 
long-term effectiveness and value for money of 
tiotropium + olodaterol Respimat® FDC.
Methods
Previous COPD models
Given the chronic nature of COPD and recurrent 
exacerbations, previous COPD models have been 
based around a Markov model structure 
[Hoogendoorn et  al. 2014]. In a Markov model, 
the current status of a patient is described using a 
discrete health state for a fixed cycle of time, dur-
ing which patients accrue the costs and benefits 
associated within this health state. Most previous 
models have utilized a cohort approach whereby 
patients were distributed to health states following 
Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) recommendations which classify 
COPD severity as GOLD stages I, II, III and IV. 
In these models, disease severity based on lung 
function is assessed after the initial improvement 
following treatment initiation. Commonly, a fixed 
rate of lung function decline is used to estimate a 
transition probability matrix that is then applied to 
obtain the posterior distribution to severity stages. 
The assumptions on long-term lung function are 
supported by clinical trial results assessing bron-
chodilator treatments, which have shown that after 
initial lung function improvement, annual decline 
in lung function does not differ significantly 
between treatments [Tashkin and Ferguson, 
2013; US Food and Drug Administration, 2015; 
European Medicines Agency, 2016]. Exacerbations 
risk, utility values, mortality and costs are then 
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estimated by GOLD stage [Oostenbrink et  al. 
2005; Rutten-Van Molken et al. 2007; Price et al. 
2011, 2013; Ariza et al. 2012].
Markov model structures are most appropriate 
when each health state can sufficiently represent 
the potential patient heterogeneity within these 
states, and the ECLIPSE study has highlighted 
the substantial heterogeneity of COPD patients 
[Vestbo et  al. 2008]. For example, two COPD 
patients classified to a GOLD stage at baseline 
may initiate treatment with lung function values at 
extreme ends of the range defining that GOLD 
stage. When assuming a constant annual decline 
in lung function following the initial improve-
ment, the time at which these two patients pro-
gress to the next severe disease stage may differ 
significantly, whereas Markov models would over-
look these differences in progression. Furthermore, 
the memoryless feature of Markov models is only 
justified when the risk of experiencing an event 
(e.g. exacerbation) in future cycles is dependent 
on the current health state, and independent of 
disease history (e.g. the number or severity of 
events in past cycles) [Drummond et al. 1999].
Based on the review of previous COPD modelling 
methods, the new model, assessing the cost- 
effectiveness of tiotropium + olodaterol Respimat® 
FDC, integrated several aspects of the previous 
models while also modifying elements common 
to the model structures of these models. Model 
development adhered to ISPOR Modelling Good 
Research Practices on model conceptualization 
[Roberts et  al. 2012] and the development of 
state-transition models [Siebert et  al. 2012]. In 
particular, the conceptualization of the model 
structure was determined by the biological under-
standing of COPD and was further informed by 
expert consultation to convert the conceptualiza-
tion into an appropriate model structure, as rec-
ommended by the guidelines.
Lung function improvement and decline
Rather than classifying a cohort of patients into 
discrete health states using a distribution of 
GOLD stages, outcomes were modelled based on 
the trough FEV1 (tFEV1) of all patients included 
in the tiotropium + olodaterol Respimat® FDC 
and tiotropium cohorts, based on patient-level 
data from the TOnado trials (see Table 1). 
Individual patient tFEV1 was tracked at baseline 
and at clinical visits through the 52-week trial 
duration, during which tFEV1 could improve 
from baseline (Figure 1). Beyond 52 weeks, 
tFEV1 was modelled assuming a constant linear 
decline by disease stage reported for the tiotro-
pium arm in the UPLIFT trial: GOLD II: 37.1 
ml/year; GOLD III: 30.7 ml/year; GOLD IV: 
24.2 ml/year (Table 2) [Tantucci and Modina, 
2012].
Classification of disease severity
In each cycle, tFEV1 was converted to a post-
bronchodilator value to calculate percentage 
FEV1 predicted to classify patients to different 
disease stages. A conversion factor of 1.16 was 
derived by comparing pre- to post-bronchodilator 
FEV1 at baseline of all patients in the TOnado 
trials. The GOLD 2007 criteria was then used for 
severity assessment defining GOLD II as 50% ⩽ 
FEV1 predicted < 80%; GOLD III as 30% ⩽ 
FEV1 predicted < 50%; and GOLD IV as FEV1 
predicted < 30%, consistent with the criteria 
used in TOnado. The classification of patient-
level FEV1 predicted values into GOLD stages 
Table 1. Baseline characteristics.
Tiotropium 5 µg Tiotropium + olodaterol 
Respimat® FDC
5/5 µg
Participants 1033 1029
Male 755 (73.1) 733 (71.2)
Pre-bronchodilator FEV1 ml 1200 ± 504 1180 ± 493
Post-bronchodilator FEV1 ml 1370 ± 521 1344 ± 505
GOLD II 517 (50.0) 508 (48.8)
GOLD III 347 (37.5) 408 (39.7)
GOLD IV 128 (12.4) 119 (11.6)
FDC, fixed-dose combination; FEV1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstruc-
tive Lung Disease
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enabled the modelling of clinical outcomes (lung 
function decline, mortality, QoL) as well as costs 
in each cycle for individual patients.
Exacerbation risk
While some previously published models in 
COPD have estimated the risk of both severe and 
moderate exacerbations by both treatment and 
GOLD stage, [Ariza et al. 2012; Price et al. 2013] 
others have estimated overall exacerbation risk 
by treatment only [Oostenbrink et al. 2005; Price 
et al. 2011] or estimated the proportion of severe 
to nonsevere exacerbations by GOLD stage 
[Hoogendoorn et  al. 2014]. These approaches 
come with limitations, in that the estimated prob-
ability of exacerbation is not affected by past 
experience of exacerbation. A recent history 
of exacerbations has been shown to be the most 
reliable predictor for future exacerbations 
[Donaldson and Wedzicha, 2006; Tashkin and 
Ferguson, 2013].
In the current model, monthly exacerbation risk 
was estimated based on a random-effects logistic 
regression analysis of patient-level data of exacer-
bation history in the 4-year UPLIFT clinical trial 
which compared treatment with tiotropium to 
placebo. Using data from the tiotropium treat-
ment group (given it was common to both the 
UPLIFT and TOnado trials), the dichotomous 
outcomes of moderate exacerbation and hospitali-
zation due to severe exacerbation within a month 
were estimated. A COPD exacerbation was 
defined as a complex of lower respiratory events/
symptoms (an increase or new onset of symptoms) 
relating to the underlying COPD, with a duration 
of 3 days or more. Moderate exacerbations were 
those that required antibiotics or systemic steroids 
without hospitalization and severe ones were those 
requiring hospitalization The explanatory varia-
bles in the regression analyses included number of 
moderate exacerbations in the previous 12 months 
(moving annual mean), number of hospitaliza-
tions due to severe exacerbation in the previous 12 
months (moving annual mean), FEV1% predicted 
(measurement closest to the beginning of a 
month), and age. Results of the logistic regression 
analysis for both moderate and severe exacer-
bation risk are reported in Table 3, which also 
Figure 1. Model structure.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; tFEV1, trough forced expiratory volume in one second.
Table 2. Clinical inputs assessed by GOLD stage.
Annual tFEV1 
decline
Utility value
GOLD II 37.1 ml 0.787 (0.771–0.802)
GOLD III 30.7 ml 0.750 (0.731–0.768)
GOLD IV 24.2 ml 0.647 (0.590–0.0695)
GOLD, Global Initiative for Chronic Obstructive Lung 
Disease; tFEV1, trough forced expiratory volume in one 
second.
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includes the random intercept distributions for 
each analysis used to make predictions of moder-
ate and severe exacerbations.
Moderate exacerbations in the previous year was 
not only a significant predictor, but a strongly sig-
nificant predictor of future moderate exacerba-
tion risk (p > 0.000). The tFEV1% predicted was 
also a statistically significant explanatory variable 
of future moderate exacerbation risk. In the severe 
exacerbation regression analysis, all explanatory 
variables included were statistically significant. 
Patients in the model were assumed to experience 
only one exacerbation (either moderate or severe) 
per 1-month cycle.
Mortality
Mortality was estimated based on two sources: a 
large trial of COPD patients, in which mortality 
was the primary outcome [Wise et al. 2013] and 
national statistics reporting mortality risk in the 
general population [Istat.It, 2015]. All-cause 
mortality was estimated from an analysis of 
TIOSPIR trial data, an international randomized 
controlled trial including 17,135 patients with 
COPD, which compared the safety and efficacy 
of tiotropium at three different doses using two 
types of inhalers [Wise et al. 2013]. The risk of 
death at 1 year in TIOSPIR was estimated for 
nine subgroups: GOLD stages II–IV combined 
with the age groups of (a) <60 years, (b) 60 ⩽ age 
< 70 years, and (c) ⩾70 years. The probabilities 
of death were compared with the mortality in the 
Italian population for the same age groups. To 
ensure an equivalent comparison, age group mor-
tality rates in the Italian general population were 
based on the weighted average mortality using the 
male–female split (males = 71.1% across all age 
groups) and age distribution within age groups 
(mean age of 65.0; SD 9.1, assuming a normal 
distribution) from the TIOSPIR trial [Wise et al. 
2013]. The risks of death in TIOSPIR and Italian 
population age groups were compared and stand-
ard mortality ratios (SMRs) were estimated for all 
nine subgroups (Table 4). Mortality was not 
adjusted by the incidence of exacerbations to pre-
vent double counting.
Costs
The base case analysis took the perspective of the 
Italian National Health Service including direct 
medical costs, where costs were expressed in 
Euros in 2015. Cost of bronchodilators and other 
medications, routine management, and costs of 
treatment of exacerbations were included in the 
analysis (Table 5). Tiotropium + olodaterol 
Respimat® FDC was not marketed in Italy at the 
time of the analysis, thus we assumed parity price 
to other LAMA/LABA FDCs; both this price 
and Tiotropium’s price were obtained from the 
AIFA database [Agenxia Italiana Del Farmaco, 
2015]. Costs of routine management included 
prescription costs (excluding bronchodilators) 
[Koleva et  al. 2007] and nonprescription drug 
Table 3. Exacerbation risk logistic regression analysis.
Moderate exacerbation risk logistic regression analysis
 Coeff SEM Z p >|z| 95% CI
Moderate exacerbation in previous year 0.2962704 0.0328924 9.01 0.000 0.2318024 0.3607383
Hospitalization in previous year 0.0421766 0.040818 1.03 0.301 −0.0378252 0.1221784
FEV1% predicted −0.0120495 0.0016381 −7.36 0.000 −0.0152602 −0.0088388
Age in months 0.000375 0.0002307 1.63 0.104 −0.0000772 0.0008272
Constant −3.2075 0.1962957 −16.34 0.000 −3.592233 −2.822768
Random intercept 0.6296274 0.0589371 0.5240898 0.7564174
Severe exacerbation risk logistic regression analysis
Moderate exacerbation in previous year 0.1723609 0.0345583 4.99 0.000 0.1046279 0.2400939
Hospitalization in previous year 0.3673385 0.0594212 6.18 0.000 0.2508752 0.4838019
FEV1% predicted −0.0506315 0.0035473 −14.27 0.000 −0.0575841 −0.043679
Age in months 0.002943 0.0004814 6.11 0.000 0.0019993 0.0038866
Constant −5.272451 0.4052518 −13.01 0.000 −6.06673 −4.478172
Random intercept 1.115954 0.0860875 0.959362 1.298106
CI, confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in one second; SEM, standard 
error of the mean.
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costs [Zaniolo et  al. 2012] which were derived 
from Italian observational studies. Costs of exac-
erbation treatment were obtained from an Italian 
observational study conducted in 25 hospitals in 
Italy in order to estimate costs associated with 
COPD exacerbations in Italy [Lucioni et  al. 
2005]. Costs of moderate and severe exacerba-
tions were applied on occurrence.
Quality of life
QoL was also assessed based on GOLD stage 
(Table 2) [Rutten-Van Molken et al. 2006] and 
the incidence of exacerbations, with utility multi-
pliers (moderate: 0.85; severe: 0.50) [Paterson 
et al. 2000] applied on occurrence for the dura-
tion of one cycle [Spencer et al. 2003].
Base case analysis
Each individual patient progressed through the 
model over time and their clinical and economic 
outcomes were aggregated by treatment cohort. 
Mean outcomes were calculated for each patient 
subgroup and stratified in terms of 10-year age 
band, GOLD stage (evolving over time) and sex. 
These average values were then weighted by the 
baseline distribution across these subgroups. 
Subgroup distribution was developed as a modifi-
able input to enable validation of the model results 
with those of other long-term clinical trials.
The base case analysis was run over a time horizon 
of 15 years, with direct medical costs and COPD 
health outcomes discounted at a rate of 3.0% 
according to the recommendations for health eco-
nomic evaluations in Italy [Fattore, 2009].
Validation
As a validation exercise, the model was run over a 
1-year time horizon to compare the model’s esti-
mate of exacerbation incidence and all-cause 
mortality with what was reported in the TOnado 
trial. A scenario analysis was also conducted in 
which the model was run using a 30 ml constant 
annual rate of lung decline across GOLD stages 
as in previous COPD models, rather than the 
GOLD-stage specific rates of decline to assess the 
impact on results.
Parameter uncertainty
Parameter uncertainty was modelled in several 
ways. For lung function improvement, patient-
level data from the TOnado trials through 52 
Table 4. COPD-related mortality risk (pooled) by age and severity stage.
Patient subgroup 365-day mortality 
in TIOSPIR
SMR compared with 
general population in Italy
Age < 60 GOLD Stage I–II 0.437% 1.15
 GOLD Stage III 1.44% 3.80
 GOLD Stage IV 3.93% 10.37
60 ⩽ age < 70 GOLD Stage I–II 1.37% 1.37
 GOLD Stage III 2.13% 2.13
 GOLD Stage IV 4.56% 4.56
Age ⩾70 GOLD Stage I–II 3.06% 0.88
 GOLD Stage III 4.00% 1.15
 GOLD Stage IV 8.43% 2.41
COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SMR, stan-
dard mortality ratio.
Table 5. Cost inputs.
Costs (2015 €)
Medication costs per month  
Tiotropium + olodaterol 
Respimat® FDC 5/5 µg
43.95
Tiotropium 5 µg 31.23
Routine management costs 
per month
 
GOLD Stage II 123.87
GOLD Stage III 135.65
GOLD Stage IV 199.03
Exacerbation treatment costs 
per episode
 
Severe exacerbation 1730.78
Moderate exacerbation 400.78
FDC, fixed-dose combination; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease.
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weeks were incorporated directly at a patient level 
and so no uncertainty around this parameter was 
modelled in sensitivity analysis. All other inputs, 
relating to lung function decline, exacerbation 
and mortality risk, as well as costs and QoL, were 
varied in probabilistic sensitivity analyses (PSAs) 
to explore the impact of parameter uncertainty on 
cost-effectiveness results. Costs were varied in the 
PSAs based on gamma distributions, lung decline 
and utility values based on beta distributions, 
SMRs based on lognormal distributions, and 
logistic regression parameters for exacerbation 
risk based on normal distributions.
Results
The model was run to assess the cost-effective-
ness of tiotropium + olodaterol Respimat® FDC 
versus tiotropium over a time horizon of 15 years 
with results presented in Table 6 in accordance 
with the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) for 
economic evaluations [Husereau et  al. 2013]. 
Comparing total costs and quality-adjusted life 
years (QALYs) per patient in the tiotropium + 
olodaterol Respimat® FDC treatment cohort 
over 15 years with the tiotropium cohort showed 
incremental costs of €1,166.95 per patient, 
incremental QALYs of 0.16 per patient, and an 
incremental cost-effectiveness ratio (ICER) of 
€7,518.49 per additional QALY over 15 years. 
PSAs showed tiotropium + olodaterol Respimat® 
FDC to be the more cost-effective treatment in 
95.2% and 98.4% of 500 simulations at thresh-
olds of €20,000 and €30,000 per QALY respec-
tively [See PSA scatterplot results in Figure 2 
and cost-effectiveness acceptability curves 
(CEAC) in Figure 3]. In deterministic sensitiv-
ity analysis (DSA), the ICER ranged from 
£2,905 to £9,621, and the severe exacerbation 
risk equation was the most sensitive parameter. 
The base case ICER was most impacted at 
shorter time horizons, with an ICER of £18,180 
at 10 years.
Table 6. Cost-effectiveness results at 15 years.
Discounted costs
per patient
Discounted QALYs
per patient
Tiotropium + olodaterol 
Respimat® FDC 5/5 µg
€27,597.77 7.43
Tiotropium 5 µg € 26,430.82 7.27
∆ Costs € 1,166.95
∆ QALYs 0.16
ICER € 7,518.46 per QALY gained
FDC, fixed-dose combination; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Figure 2. PSA scatterplot.
Olo, olodaterol; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life years; Tio, tiotropium.
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The more favourable distribution over time of 
patients to the less severe GOLD stages based on 
TOnado data was reflected in the higher mean 
life-years per patient with tiotropium + olodaterol 
Respimat® FDC versus tiotropium (12.24 versus 
12.07 respectively), as shown in Table 7. Similarly, 
the mean number of exacerbation-free months 
and QALYs per patient (11.36 versus 11.32; 7.44 
versus 7.23) were higher and the number of mod-
erate and severe exacerbations per patient-year 
was lower with tiotropium + olodaterol Respimat® 
FDC compared with tiotropium (0.411 versus 
0.415; 0.21 versus 0.24 respectively).
To validate the model’s results, the model was 
run for a period of 1 year to compare with results 
from the TOnado trial. Estimating the number of 
total exacerbations per patient-year using the 
logistic regression equations derived from 
UPLIFT trial data, the mean number of total 
exacerbations in the model fell within the confi-
dence intervals of the results reported in TOnado 
[0.462 versus 0.509 per patient (95% CI 0.432, 
0.599)] for the tiotropium arm. All-cause mortal-
ity estimated in the model for the tiotropium arm 
was slightly higher than rates reported in TOnado 
at 1 year (3.2% versus 1.7%).
As a scenario analysis, the model was run using a 
30 ml constant annual rate of lung decline across 
GOLD stages, consistent with a previous COPD 
model deriving lung function decline from 
UPLIFT [Tantucci and Modina, 2012]. The 
mean number of moderate exacerbations per 
patient-year in the tiotropium arm was only 
slightly changed (0.402 versus 0.405) while mean 
severe exacerbations were unchanged. All-cause 
mortality rates at 15 years were only marginally 
impacted (tiotropium + olodaterol Respimat® 
FDC: 45.3%; tiotropium: 46.8%) compared with 
the base case (tiotropium + olodaterol Respimat® 
FDC: 45.6%; tiotropium: 47.1%).
Figure 3. Cost-effectiveness acceptability curve.
Olo, olodaterol; QALY, quality-adjusted life years; Tio, tiotropium.
Table 7. Clinical outcomes at 15 years: base case.
Life-years 
per patient
Exacerbation-free 
months per patient 
per year
Nonsevere 
exacerbations per 
patient-year
Severe 
exacerbations 
per patient-year
Tiotropium + olodaterol 
Respimat® FDC 5/5 µg
12.24 11.36 0.411 0.21
Tiotropium 5 µg 12.07 11.32 0.415 0.24
FDC, fixed-dose combination.
Table 8. Clinical outcomes versus TOnado trial.
Total exacerbations 
per patient-year
All-cause 
mortality
TOnado, 1 year 0.509 1.6%
Model, 1 year 0.462 3.2%
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Discussion
The cost-effectiveness model incorporated 
patient-level data from over 2000 participants of 
the TOnado trials. This more granular approach 
enabled a reflection of the heterogeneity in the 
level of short-term lung function improvement 
following bronchodilator treatment initiation. 
Treatment benefit of tiotropium + olodaterol 
Respimat® FDC was modelled based on the lung 
function improvement observed in the treatment 
cohort of the TOnado trial, and the benefit in 
terms of exacerbation risk was modelled indi-
rectly. Instead of estimating exacerbation inci-
dence merely by GOLD stage, the current 
approach accounted for patient data on age and 
lung function over time as well as history of 
recent moderate and severe exacerbations. 
Rather than being mere indicators of COPD 
severity, the incidence of past exacerbations was 
used to predict future exacerbations, and by pre-
venting an exacerbation now, future exacerba-
tions are thus prevented.
The lung function treatment benefit reported for 
patients treated with tiotropium + olodaterol 
Respimat® FDC in the 52-week TOnado trials 
translated into lower risk of exacerbations and 
lower mortality. The ICER of €7,518/QALY 
obtained in the comparison of tiotropium + olo-
daterol Respimat® FDC versus tiotropium is well 
below commonly used cost-effectiveness thresh-
olds. These results changed only marginally 
when parameter values were varied in the DSA 
for inputs related to costs, utilities, mortality and 
moderate exacerbations (1–6% change versus 
base case ICER). The results were most sensi-
tive to variations to the parameters of the severe 
exacerbation risk equation (28–61% change 
versus base case ICER).
The modelling methods improved upon the 
approaches taken in previous models, which were 
based on a strict, cohort-based Markov structure 
and relied on a memoryless estimation of transi-
tion probabilities. Furthering the objective of 
more appropriately modelling disease progression 
by reflecting patient heterogeneity at baseline and 
post-improvement, the long-term lung function 
decline was applied based on COPD severity 
rather than using a single rate of decline for all 
patients. Excess mortality rates took into account 
data on age and GOLD stage for individual 
patients to more accurately estimate risk of death 
during the time horizon.
The consistency of the model results was vali-
dated using the ISPOR-SMDM good research 
practices on model transparency and validation 
[Eddy et al. 2012]. This validation involved tests 
of face validity evaluating model structure, data 
sources, assumptions and results. In addition, 
validation was expanded to include external valid-
ity, comparing model results with those observed 
in other clinical trials. When comparing the model 
results to what was observed in the TOnado trial, 
overall the model predicted similar rates of all-
cause mortality to what has been observed in the 
trial, despite only using Italian life tables to esti-
mate mortality rather than reflecting the multiple 
nationalities of TIOSPIR patients. Rate of exac-
erbations per patient-year were also closely 
aligned between the model and what observed in 
the TOnado trial.
Modelling over a time horizon of 15 years intro-
duces additional uncertainty into the analysis 
given the assumption of indefinite use of bron-
chodilators. This assumption did not allow the 
model to account for new treatments entering the 
market, which might impact outcomes over the 
long term, although this is inherent in most cost-
effectiveness analysis modelling over the long 
term. However, a time horizon extending to 15 
years is reasonable given that COPD is a chronic 
condition for which patients receive life-long 
treatment. The mean age of patients in the 
TOnado trials was 64 years old and so the 15-year 
time horizon could be expected to cover a rele-
vant duration even for the most severe patients at 
baseline (GOLD IV) of which approximately 
40% were still alive at 15 years.
Furthermore, treatment switching due to speci-
fied stopping rules (e.g. following a 4-point drop 
on the St George’s Respiratory Questionnaire 
(SGRQ)) were not included in the analysis, which 
may have affected the outcomes predicted in the 
model. The model focussed exclusively on lung 
function following treatment initiation without 
taking into account other treatment effects, which 
can be both beneficial and harmful and could 
impact some clinically-relevant outcomes. Future 
models would benefit from including available 
data on treatment adherence and its impact on 
clinical outcomes as well as costs.
Given the focus on lung function improvement as 
the primary outcome in previous economic evalu-
ations, the patient-level approach taken in the 
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current model based on two large, well-matched 
patient cohorts demonstrated a feasible method of 
reflecting the heterogeneity of this improvement.
Conclusion
The cost-effectiveness model incorporated 
patient-level lung function improvement data 
observed in a recent clinical trial of tiotropium + 
olodaterol Respimat® FDC, a newly developed 
combination bronchodilator treatment in COPD. 
Lung function improvement assessed at clinical 
trial visits was used in combination with individ-
ual patient characteristics and history of exacer-
bations to estimate both moderate and severe 
exacerbations and mortality based on statistical 
analyses of large international clinical trial data in 
COPD. The analysis demonstrated that in the 
long term when comparing tiotropium + olo-
daterol Respimat® FDC with tiotropium alone, 
the number of moderate and severe exacerba-
tions, and the number of patients in the most 
severe GOLD stages was reduced, thus increasing 
the number of life-years and QALYs. These ben-
efits were achieved at a cost below cost-effective-
ness thresholds used in Italian health care 
decision-making [Fattore, 2009].
In the analysis, the benefits observed in a short-
term clinical trial impacted long-term outcomes, 
a finding supported by the current understanding 
of COPD. Future cost-effectiveness models 
would benefit from using the current approach, 
which robustly reflects this current understanding 
of COPD.
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